Ac Immune Stock EBITDA
| ACIU Stock | USD 3.38 0.09 2.74% |
AC Immune fundamentals help investors to digest information that contributes to AC Immune's financial success or failures. It also enables traders to predict the movement of ACIU Stock. The fundamental analysis module provides a way to measure AC Immune's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to AC Immune stock.
| Last Reported | Projected for Next Year | ||
| EBITDA | -51.8 M | -49.2 M |
ACIU | EBITDA |
AC Immune Company EBITDA Analysis
AC Immune's EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Current AC Immune EBITDA | (51.83 M) |
Most of AC Immune's fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, AC Immune is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
ACIU EBITDA Driver Correlations
Understanding the fundamental principles of building solid financial models for AC Immune is extremely important. It helps to project a fair market value of ACIU Stock properly, considering its historical fundamentals such as EBITDA. Since AC Immune's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of AC Immune's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of AC Immune's interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
| Competition |
ACIU Ebitda
Ebitda |
|
According to the company disclosure, AC Immune reported earnings before interest,tax, depreciation and amortization of (51.83 Million). This is 105.91% lower than that of the Biotechnology sector and 151.75% lower than that of the Health Care industry. The ebitda for all United States stocks is 101.33% higher than that of the company.
ACIU EBITDA Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses AC Immune's direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of AC Immune could also be used in its relative valuation, which is a method of valuing AC Immune by comparing valuation metrics of similar companies.AC Immune is currently under evaluation in ebitda category among its peers.
AC Immune Current Valuation Drivers
We derive many important indicators used in calculating different scores of AC Immune from analyzing AC Immune's financial statements. These drivers represent accounts that assess AC Immune's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of AC Immune's important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 581.8M | 329.2M | 338.2M | 157.5M | 356.0M | 603.7M | |
| Enterprise Value | 391.1M | 170.5M | 258.9M | 128.7M | 281.0M | 498.1M |
AC Immune ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, AC Immune's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to AC Immune's managers, analysts, and investors.Environmental | Governance | Social |
AC Immune Institutional Holders
Institutional Holdings refers to the ownership stake in AC Immune that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of AC Immune's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing AC Immune's value.| Shares | Millennium Management Llc | 2024-06-30 | 106.4 K | Two Sigma Investments Llc | 2024-06-30 | 99.3 K | Eversept Partners, Llc | 2024-09-30 | 99.3 K | Alps Advisors Inc | 2024-06-30 | 77.4 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 57.1 K | Geode Capital Management, Llc | 2024-06-30 | 54.8 K | Cubist Systematic Strategies, Llc | 2024-06-30 | 54.6 K | Jump Financial Llc | 2024-06-30 | 41.3 K | Citadel Advisors Llc | 2024-06-30 | 34.8 K | Bvf Inc | 2024-09-30 | 19.5 M | Blackrock Inc | 2024-06-30 | 2.6 M |
ACIU Fundamentals
| Return On Equity | -0.31 | ||||
| Return On Asset | -0.12 | ||||
| Profit Margin | (0.97) % | ||||
| Operating Margin | 0.29 % | ||||
| Current Valuation | 150.34 M | ||||
| Shares Outstanding | 98.94 M | ||||
| Shares Owned By Insiders | 21.83 % | ||||
| Shares Owned By Institutions | 28.81 % | ||||
| Number Of Shares Shorted | 984.46 K | ||||
| Price To Earning | (16.96) X | ||||
| Price To Book | 2.21 X | ||||
| Price To Sales | 7.94 X | ||||
| Revenue | 14.8 M | ||||
| Gross Profit | (56.4 M) | ||||
| EBITDA | (51.83 M) | ||||
| Net Income | (54.23 M) | ||||
| Cash And Equivalents | 154.15 M | ||||
| Cash Per Share | 1.83 X | ||||
| Total Debt | 3.5 M | ||||
| Debt To Equity | 0.01 % | ||||
| Current Ratio | 13.28 X | ||||
| Book Value Per Share | 1.30 X | ||||
| Cash Flow From Operations | (60.41 M) | ||||
| Short Ratio | 12.24 X | ||||
| Earnings Per Share | (0.45) X | ||||
| Target Price | 9.02 | ||||
| Number Of Employees | 133 | ||||
| Beta | 1.28 | ||||
| Market Capitalization | 325.52 M | ||||
| Total Asset | 182.81 M | ||||
| Retained Earnings | (316.2 M) | ||||
| Working Capital | 111.58 M | ||||
| Current Asset | 160 M | ||||
| Current Liabilities | 11 M | ||||
| Net Asset | 182.81 M |
About AC Immune Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze AC Immune's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of AC Immune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of AC Immune based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for ACIU Stock Analysis
When running AC Immune's price analysis, check to measure AC Immune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy AC Immune is operating at the current time. Most of AC Immune's value examination focuses on studying past and present price action to predict the probability of AC Immune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move AC Immune's price. Additionally, you may evaluate how the addition of AC Immune to your portfolios can decrease your overall portfolio volatility.